Omico’s Post

We are so excited to share that over 7,500 patients have been referred to PrOSPeCT*, by over 800 clinicians! (*Precision Oncology Screening Platform Enabling Clinical Trials) This means that the total number of patients referred to Omico initiatives now exceeds 15,000! These 15,000+ individuals sought additional information about their cancer through comprehensive genomic profiling, along with the possibility of being matched with targeted therapies that may have otherwise gone undiscovered for them. We thank every single patient, family, health care professional, Omico employee, partner and stakeholder for their commitment and support to date. We are fully committed to supporting the entire cancer community to make the most of the PrOSPeCT initiative, which is aiming to provide free comprehensive genomic profiling to 23,000 Australians with advanced, incurable or poor prognosis cancers by the end of 2025. Visit www.omico.com.au to learn more. #CancerMeetsItsMatch #MeetThePatientsThatMatched #PrecisionOncology #ClinicalTrials

A HUGE THANK YOU to all oncologists, researchers and biopharma companies who have worked closely with us this year. Thank you for your support and confidence in Guardant Health’s comprehensive genomic profiling tests which are transforming cancer care across all stages of the disease. As we move into 2024, we look forward to your continued support in guiding treatment decisions for patients with cancer in Asia, Middle East and Africa.   Patient centricity is the heart of all that we do. We serve each patient like a family member.   Visit us at https://lnkd.in/gHNdYtQN to find out more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer.   #guardanthealth #guardanthealthamea #thankyou #oncologists #medicaloncologists #researchers #biopharma #cancerpatients #puttingpatientsfirst #guardant360 #guardant360tissuenext #guardantreveal #guardantresponse #shield #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #liquidissolid

Yesterday marked #WorldCancerDay, centered around the theme "Close the Care Gap." At Exactis Innovation, we're dedicated to narrowing the gap between cancer patients and life-saving drugs. Leveraging our Databank for Real-World Evidence (#RWE) studies, we contribute to bridging the divide by delivering timely results to healthcare decision-makers, making our healthcare system more efficient by getting the best treatments to patients, faster. Real-world evidence and real-world data are formidable tools in the arsenal of decision-makers, offering insights into how innovative cancer therapies perform beyond clinical trials. In the fight against cancer, it's imperative to utilize all available tools to prevent and treat this disease. This is our tool of choice. 👥 Let's unite in the battle against cancer and work towards a future where the care gap is closed for good. To learn more or connect with us, visit our website: exactis.ca. #CloseTheCareGap #RealWorldEvidence #RWD #HEOR #CancerResearch

Last month's CDDF-EORTC Joint Workshop on Innovation & Access in #RareCancers, led by EORTC President Prof. Winette van der Graaf and Prof. Ruth Plummer, brought together key stakeholders to discuss the current state of play in #ClinicalTrials. The workshop provided a platform for collaborative insights on improving access to innovative therapies for rare cancer patients.   📑 Read the full executive summary here: https://lnkd.in/eAksST_n   #CancerResearch #Oncology

Targeted treatments can be six times more effective than older chemotherapies, benefiting 1 in 3 people now compared to just 1 in 20 two decades ago. Precision oncology is driving these advances, as patients are matched to new, personalised treatments based on their cancer’s unique features. Participating in a clinical trial not only provides faster access to cutting edge treatments – these trials also play a critical role in advancing the fight against cancer. Meet Beth Ivimey, a courageous individual who, after undergoing comprehensive genomic profiling (CGP), was matched to a clinical trial with a targeted therapy. For more information, download the patient information booklet. It's a great resource to have handy when you speak to your cancer doctor (oncologist) about your eligibility for free CGP with Omico: https://lnkd.in/g_2iJ-2r Or learn more about how it works and eligibility requirements by visiting the Omico website at https://lnkd.in/g8XM4XRd #Omico #CancerMeetsItsMatch #CGP #ComprehensiveGenomicProfiling #MeetThePeopleThatMatched

Secondary cancer risks from CAR-T therapy are a concern. BUT new research shows these concerns may be overstated. Here's just how rare that circumstance is: Only 0.09% of over 5,500 cases were linked to CAR-T cells. ➡️ New research challenges these FDA warnings as a study of over 5,500 patients, led by Memorial Sloan Kettering, found no significant increase in the risk of secondary cancers compared to standard treatments. Only 5.8% of patients developed secondary cancers, with just 0.09% involving T-cell malignancies linked to CAR-T. 👉 Researchers suggest that prior treatments and longer patient lifespans, rather than CAR-T itself, may contribute to the cancer risk. Experts now call for a reassessment of the FDA warning labels, arguing they may unnecessarily discourage patients from this life-saving therapy. Link to the article below. Brilliant news for patients! #celltherapy #oncology #biotech #CGTweekly

🔔 📣 [Executive Summary: CDDF-EORTC Joint Workshop on Innovation and Access in #RareCancers (23-24 September 2024, Amsterdam, NL)] The Cancer Drug Development Forum (CDDF) is delighted to announce that the executive summary of its recent workshop on Rare Cancers has been published today and is available to all stakeholders. https://lnkd.in/eAksST_n   This collaborative initiative between CDDF and EORTC focused on the current state of play in #clinicaltrials and exchanged #multistakeholder perspectives in order to improve access to innovative therapies for #patients with rare cancers. A multi-stakeholder group of experts provided insights on important topics in rare cancers such as the existing challenges, ongoing collaborations, unmet needs, innovative clinical trial designs and potential solutions to improve patient access. To learn more about our discussions, read the executive summary and feel free to share your thoughts with us. 🔴 Read the executive summary: https://lnkd.in/eAksST_n 🔴 Have a quick glimpse of the September workshop: https://lnkd.in/e_yK5tgZ #collaboration #Oncology #cancertreatments #rarecancers #drugdevelopment #patientaccess EORTC - European Organisation for Research and Treatment of Cancer

🌟 Excited for #ASCO24! 🌟 This week I'm thrilled to be part of ASCO 2024, following the course of new therapeutic innovations in oncology. The theme "The Art and Science of Cancer Care: From Comfort to Cure" promises updates on how as a collective we are making significant strides in cancer treatment. Potentially practice-changing research highlights the commitment of the #Oncology community in addressing the unmet needs of patients by bringing forward new options that improve treatment outcomes. Events like ASCO24 are catalysts for progress, showcasing the dedication and breakthroughs of research. I am incredibly proud of our teams at #GSK, who have advanced research various areas of Oncology. Their unwavering commitment and innovation are making a positive impact on the lives of many affected by these diseases. The significant unmet need in oncology and the opportunities for scientific breakthroughs underscore the importance of partnerships. By collaborating with others, we can achieve far more than we ever could alone. These partnerships are essential in driving the progress needed to make a real difference for patients. Over the next few days, I look forward to connecting with colleagues and the healthcare community at ASCO 2024. Together, we can unite in our fight against cancer and continue this forward momentum to bring hope and better outcomes to patients worldwide. #ASCO24 #Partnering #Oncology #CancerInnovation #MultipleMyeloma #HealthcareInnovation

Today celebrates all our research teams around the world that are endlessly decimated their time, knowledge and brilliance to build the cancer therapeutics of the future. Every step forward is a gain for cancer patients, and it takes a village, I should say a full town, with multiple players, to successfully convert innovation into a real option for cancer patients. This is why we need to all support and encourage our science teams, labs, research departments and biotech research teams to persist and never give up. At NKILT Therapeutics, Inc., under the lead of our CEO Raphaël G. Ognar, MSc MBA, and the whole leadership and science teams, we continue to push boundaries and give it all to get a chance to bring new options to more cancer patients... because health equity is key, because patients need more, because they deserve it! #worldcancerresearchday2024 #cancerresearch #celltherapy #cancerpatients #healthequity

🔔 📣  [Register Today for the CDDF Webinar on #ClinicalResearch in Central and Eastern Europe - Monday 12 February 2024, 17:00 (CET) / 11:00 (EST)] Registration is open for the upcoming webinar on “Clinical Research in Central and Eastern Europe: Realising the Opportunities.” Along with a Q&A session moderated by Axel Glasmacher and Susan Bhatti, the following speakers will present interesting perspectives on the topic: 🎤 Susan Bhatti (Merck BV): "What do we need to change to have smarter, faster, more patient centered trials in Europe" 🎤 Mark Lawler (Queen’s University Belfast & CDDF): "Deploying data to understand cancer research challenges and opportunities in Central and Eastern Europe" 🎤 Wiktor Janicki (AstraZeneca): "Does Poland have the potential to become the next cancer research hub?"   🗓 Date & Time: Monday 12 February 2024 at 17:00 (CET) / 11:00 (EST). 📝 Webinar outline: https://lnkd.in/e7wwsJCr 🔔 Registration: https://lnkd.in/ej2j5paw   This webinar is designed to give a pre-view of the discussions that are going to take place during the CDDF Multi-stakeholder workshop on Clinical Research in Central and Eastern Europe: New Approaches for the Next Level of Development on 15-16 April 2024 in Krakow, Poland (hybrid). 📝Workshop program: https://lnkd.in/eMushRjM 🔔Registeration: https://lnkd.in/enTSTYDG Engage in meaningful discussions, network with multi-stakeholder experts, and gain insights from thought-provoking presentations. Collaboration is key to improve cancer drug development for patients. #oncology #cancerresearch #clinicaltrials #patientaccess